Pharmaceuticals

Trump Strikes Drug Deal With Regeneron

Is Trump's drug pricing push a landmark win for patients or just cosmetic deals that leave Big Pharma in control?

Published APR 24

story

Above: President Donald Trump after signing a deal with Regeneron on April 23, 2026. Image credit: Brendan Smialowski/AFP/Getty Images

The Spin

Pro-Trump narrative

Every single one of the 17 pharmaceutical companies that got letters last year has now agreed to lower drug prices to most-favored-nation rates — and Regeneron is the latest to fall in line. Trump has delivered a massive win for American patients who've been paying way too much for way too long. The administration just proved that real pressure gets real results on health care affordability.

Kush Desai on X

Reverend Jordan Wells on X

Anti-Trump narrative

These voluntary, company-by-company MFN deals are opaque, short-term and do nothing to fix the root causes of sky-high drug prices. Doctors overwhelmingly see TrumpRx as no better than GoodRx, with 54% calling it cosmetic and only 5% believing it tackles underlying pricing problems. Big Pharma still sets prices at will, and no amount of handshake agreements changes that dynamic.

Patients For Affordable Drugs Physician's Weekly